Jul 2, 2026 11:45AM

Jul 2, 2026 11:45AM

Apr 29, 2026 11:50AM

Mar 24, 2026 07:00AM

Dec 8, 2025 07:00AM

Oct 1, 2025 09:35AM

Sep 16, 2025 07:00AM Newron presents H1 2025 results and provides business update

Aug 12, 2025 07:00AM

May 12, 2025 07:00AM

Sep 19, 2024 07:00AM

Mar 19, 2024 07:00AM

Aug 4, 2023 07:00AM

Mar 14, 2023 07:00AM

Sep 15, 2022 07:00AM Newron provides H1 2022 results and updates on R&D and business activities

Mar 15, 2022 07:00AM

Sep 16, 2021 07:00AM

May 20, 2021 07:00AM

May 4, 2021 07:00AM

Apr 1, 2021 07:00AM

Mar 16, 2021 07:00AM

Mar 15, 2021 07:00AM Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients

Jan 21, 2021 07:00AM

Sep 15, 2020 07:00AM

Aug 11, 2020 07:00AM

Mar 11, 2020 07:00AM

Mar 5, 2020 07:00AM

Jan 9, 2020 07:00AM

Dec 9, 2019 11:54AM Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data

Nov 19, 2019 07:00AM

Sep 12, 2019 07:00AM

May 28, 2019 07:00AM

Mar 5, 2019 07:00AM

Mar 1, 2018 01:00AM

Dec 11, 2017 07:00AM

Oct 6, 2017 07:00AM Newron Pharmaceuticals Supports Rett Syndrome Awareness Month this October

Sep 14, 2017 07:00AM

Jul 11, 2017 07:30AM

May 17, 2017 01:00AM

Apr 11, 2017 01:00AM

Mar 28, 2017 11:31AM

Mar 25, 2017 07:00PM

Mar 21, 2017 02:30PM FDA Approves Xadago® (Safinamide) for Parkinson’s Disease (PD) Patients

Mar 2, 2017 07:00AM

Jan 3, 2017 11:31AM

329,632 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All